Beyond the Big Tech Platform Wars: The Fringe Economy from AI Cooling to Nuclear FusionGlobal Report·1 day ago, 04:18 AMZYME-1.03%TT+1.29%
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 | ZYME Stock NewsStockTitan·Jul 15 at 09:00 PMTBPH+0.30%ZYME-1.03%
Major Theravance Biopharma Investor Makes Notable Stock MoveTip Ranks·Jul 8 at 09:02 PMTBPH+0.30%ZYME-1.03%
Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37Tip Ranks·Jun 30 at 04:55 AMZYME-1.03%TBPH+0.30%
Zymeworks agrees to buy Theravance Biopharma for $929mPharmaceutical Business Review·Jun 30 at 03:00 AMTBPH+0.30%ZYME-1.03%
Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% UpsideTradingView·Jun 29 at 05:20 PMZYME-1.03%
Zymeworks to acquire Theravance Biopharma for USD 17 per share in USD 929 million dealPUBT·Jun 29 at 05:00 AMTBPH+0.30%ZYME-1.03%
13:36 ET$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)prnewswire·Jun 29 at 12:37 PMTBPH+0.30%ZYME-1.03%
10:02 ETShareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholdersprnewswire·Jun 29 at 09:03 AMTBPH+0.30%ZYME-1.03%
Zymeworks’ TBPH Acquisition Seen as Cash-Flow Accretive, Supports Buy Rating and Unchanged $34 Price TargetTip Ranks·Jun 29 at 09:55 AMZYME-1.03%TBPH+0.30%
